Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 608

1.

Tenofovir: new indication. For first-line antiretroviral therapy: wait and see.

[No authors listed]

Prescrire Int. 2004 Oct;13(73):180-2.

PMID:
15499699
2.

Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.

[No authors listed]

Prescrire Int. 2004 Aug;13(72):144-50.

PMID:
15532140
3.

Results of the ALBI trial: a randomized comparison of stavudine/didanosine, zidovudine/lamivudine and alternating treatment in antiretroviral-naive patients.

Molina JM, Chêuc G, Ferchal F, Journot V, Pellegrin I, Sombardier MN, Rancinan C, Cotte L, Madelaine I, Debord T, Decazes JM; ALBI (ANRS 070) Study Group.

Antivir Ther. 1999;4 Suppl 3:71-4.

PMID:
16021874
4.

Safety and efficacy of two different triple drug combinations in which either lamivudine or didanosine were administered with stavudine plus indinavir.

Villalba N, Gómez-Cano M, Casas E, Soriano V, Valencia E, González-Lahoz J.

AIDS. 1997 Dec;11(15):1896-7. No abstract available.

PMID:
9412717
5.

High virological failure rate in HIV patients after switching to a regimen with two nucleoside reverse transcriptase inhibitors plus tenofovir.

Pérez-Elías MJ, Moreno S, Gutiérrez C, López D, Abraira V, Moreno A, Dronda F, Casado JL, Antela A, Rodríguez MA.

AIDS. 2005 Apr 29;19(7):695-8.

PMID:
15821395
6.

[Observational study on the efficacy of the application of two classical regimens of triple antiretroviral therapy].

Eiros Bouza JM, Ortega Lafont M, Ortiz de Lejarazu R, Bachiller Luque P, de Luis Román DA.

An Med Interna. 2003 May;20(5):239-42. Spanish.

PMID:
12831297
8.

The ALBI trial: a randomized controlled trial comparing stavudine plus didanosine with zidovudine plus lamivudine and a regimen alternating both combinations in previously untreated patients infected with human immunodeficiency virus.

Molina JM, Chêne G, Ferchal F, Journot V, Pellegrin I, Sombardier MN, Rancinan C, Cotte L, Madelaine I, Debord T, Decazes JM.

J Infect Dis. 1999 Aug;180(2):351-8.

9.

Guide to major clinical trials of antiretroviral therapy administered to patients infected with human immunodeficiency virus.

Spooner KM, Lane HC, Masur H.

Clin Infect Dis. 1996 Jul;23(1):15-27. Review. No abstract available.

10.

Hydroxyurea in combination with didanosine and stavudine in antiretroviral-experienced HIV-infected subjects with a review of the literature.

Rossero R, Asmuth DM, Grady JJ, McKinsey DS, Green S, Andron L, Pollard RB.

Int J STD AIDS. 2003 May;14(5):350-5.

PMID:
12803944
11.

Antiretroviral efficacy and virological profile of a zidovudine/lamivudine/tenofovir disoproxil fumarate combination therapy in antiretroviral-naive patients.

Masquelier B, Neau D, Boucher S, Lavignolle-Aurillac V, Schrive MH, Recordon-Pinson P, Ragnaud JM, Fleury H.

Antivir Ther. 2006;11(6):827-30.

PMID:
17310827
12.

Virologic response of zidovudine, lamivudine, and tenofovir disoproxil fumarate combination in antiretroviral-naive HIV-1-infected patients.

Rey D, Krebs M, Partisani M, Hess G, Cheneau C, Priester M, Bernard-Henry C, de Mautort E, Lang JM.

J Acquir Immune Defic Syndr. 2006 Dec 15;43(5):530-4.

PMID:
17057610
14.

Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails.

Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Piyavong B, Chumpathat N, Chantratita W.

Clin Infect Dis. 2007 Feb 1;44(3):447-52. Epub 2006 Dec 27.

15.
16.

Initiation of antiretroviral therapy: implications of recent findings.

Saag MS.

Top HIV Med. 2004 Jul-Aug;12(3):83-8. Review.

17.

Emtricitabine: new preparation. An antiretroviral very similar to lamivudine.

[No authors listed]

Prescrire Int. 2005 Apr;14(76):54-6.

PMID:
15875341
18.

Emtricitabine: a new nucleoside analogue for once-daily antiretroviral therapy.

Cahn P.

Expert Opin Investig Drugs. 2004 Jan;13(1):55-68. Review.

PMID:
14680453
19.

Emergence of zidovudine and multidrug-resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naive patients receiving stavudine plus didanosine combination therapy. STADI Group.

Pellegrin I, Izopet J, Reynes J, Denayrolles M, Montes B, Pellegrin JL, Massip P, Puel J, Fleury H, Segondy M.

AIDS. 1999 Sep 10;13(13):1705-9.

PMID:
10509572
20.

Tenofovir disoproxil fumarate.

Chapman T, McGavin J, Noble S.

Drugs. 2003;63(15):1597-608. Review.

PMID:
12887265
Items per page

Supplemental Content

Write to the Help Desk